Core Viewpoint - Enhua Pharmaceutical has received approval from the National Medical Products Administration for the supplementary application of Sulpiride Hydrochloride Tablets, confirming that the drug meets the consistency evaluation of quality and efficacy for generic drugs [2] Group 1 - The approval notification was issued recently, indicating a positive regulatory development for the company [2] - The drug has successfully passed the consistency evaluation, which is crucial for generic medications in ensuring they are equivalent to their branded counterparts [2]

Group 1 - China Pacific Insurance has received approval from the financial regulatory authority for Wang Yuhua to serve as a director [1] - Shanghai Bank announced that the regulatory authority has approved Chen Lei's qualification as vice president [2] - Shanghai HuGong has decided to terminate the "Aerospace Equipment Manufacturing Base" fundraising project due to significant changes in project feasibility [3] Group 2 - Dongwang Times plans to reduce its stake by up to 1.20% through share sales [4] - Zhinancun intends to increase its capital by 100 million yuan in its wholly-owned subsidiary, Maigao Securities [5] - Jinxinnong reported a sales revenue of 115 million yuan from pig sales in November [6] Group 3 - Tiantan Biological has completed the Phase III clinical trial of its human prothrombin complex, showing good efficacy and safety for hemophilia B patients [7] - Beijete's subsidiary has signed a framework agreement for equity acquisition to gain control of Yunnan Wenye Nonferrous Metals [8] - Zhongsheng Pharmaceutical's RAY1225 injection has received approval for a new clinical trial indication for treating metabolic-associated fatty liver disease [9] Group 4 - Enhua Pharmaceutical's hydrochloride sulpiride tablets have passed the consistency evaluation for generic drugs [10] - Shenkong Co. plans to invest 60 million yuan in a semiconductor industry fund [11] - Lianhuan Pharmaceutical's subsidiary has received approval for its drug to pass the consistency evaluation for generic drugs [12] Group 5 - Dazhong Transportation has received approval to issue debt financing tools totaling 4.5 billion yuan [13] - Jintian Titanium Industry plans to invest 50 million yuan in an industry merger and acquisition fund [14] - Changchun Gas has committed over 1.7 billion yuan to gas facility upgrades [15] Group 6 - Laimei Pharmaceutical's innovative anti-cancer drug "Nano Carbon Iron" has received approval for clinical trials [16] - Longquan Co. has signed supply contracts worth approximately 50.76 million yuan for nuclear power components [17] - Igor plans to distribute a cash dividend of 1 yuan per 10 shares [18] Group 7 - Xingfa Group's subsidiary has signed a processing agreement for 80,000 tons of lithium iron phosphate [20] - Yunjigroup's director Wang Wanfeng has resigned for personal reasons [21] - Saiseng Pharmaceutical's application for the listing of a new drug has been accepted by the regulatory authority [22] Group 8 - Xinhua Medical has obtained registration certificates for two new medical devices [23] - Chaoying Electronics plans to invest 100 million USD in its Thai subsidiary for an AI circuit board expansion project [24] - Suzhou Planning's application to acquire 100% of Dongjin Aviation has been accepted by the Shenzhen Stock Exchange [25]

Core Viewpoint - Enhua Pharmaceutical has received approval from the National Medical Products Administration for the supplementary application of Sulfobutyl Ether Beta-Cyclodextrin Tablets, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Company Summary - Enhua Pharmaceutical's Sulfobutyl Ether Beta-Cyclodextrin Tablets are indicated for the treatment of chorea, Tourette syndrome, and senile psychosis, and can also be used for ethanol intoxication [1]

Core Points - Enhua Pharmaceutical (002262.SZ) announced the approval of its hydrochloride sulpiride tablets by the National Medical Products Administration, allowing the drug to pass the consistency evaluation of quality and efficacy for generic drugs [2] - The hydrochloride sulpiride tablets are indicated for conditions such as chorea, Tourette syndrome, and senile psychosis, and can also be used for ethanol intoxication [2] - The company has invested approximately 5.7 million RMB in research and development for this product [2]